Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women?
- 24 November 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 114 (2) , 210-225
Abstract
Cardiovascular disease (CVD) is the primary cause of death among men and women worldwide. Nevertheless, our comprehension of how CVD progresses in women and elicits clinical outcomes is lacking, leading CVD to be under-diagnosed and under-treated in women. A clear example of this differential presentation of CVD pathophysiologies in females is the strikingly higher prevalence of heart failure with preserved ejection fraction (HFpEF). Women with a history of pre-eclampsia or those who present with co-morbidities such as obesity, hypertension, and diabetes mellitus are at increased risk of developing HFpEF. Long understood to be a critical CVD risk factor, our understanding of how gender differentially affects the development of CVD has been greatly expanded by extensive genomic and transcriptomic studies. These studies uncovered a pivotal role for differential microRNA (miRNA) expression in response to systemic inflammation, where their co-ordinated expression forms a post-transcriptional regulatory network that instigates microcirculation defects. Importantly, the potential sex-biased expression of the given miRNAs may explain sex-specific cardiovascular pathophysiologies in women, such as HFpEF. Sex-biased miRNAs are regulated by oestrogen (E2) in their transcription and processing or are expressed from loci on the X-chromosome due to incomplete X-chromosome inactivation. Interestingly, while E2-induced miRNAs predominantly appear to serve protective functions, it could be argued that many X-linked miRNAs have been found to challenge microvascular and myocardial integrity. Therefore, menopausal E2 deficiency, resulting in protective miRNA loss, and the augmentation of X-linked miRNA expression, may well contribute to the molecular mechanisms that underlie the female-specific cardiovascular aetiology in HFpEF.Keywords
Funding Information
- Dutch Heart Foundation (2013T084)
- Dutch Kidney Foundation (14OIP13)
This publication has 196 references indexed in Scilit:
- High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetesDiabetologia, 2012
- MicroRNA changes in human arterial endothelial cells with senescence: Relation to apoptosis, eNOS and inflammationExperimental Gerontology, 2012
- Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cellsCancer Letters, 2011
- Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fractionClinical Research in Cardiology, 2011
- Inflammatory Markers and Incident Heart Failure Risk in Older AdultsJACC, 2010
- microRNA-221 regulates high glucose-induced endothelial dysfunctionBiochemical and Biophysical Research Communications, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Current perspectives in intronic micro RNAs (miRNAs)Journal of Biomedical Science, 2005
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998